Tim-3 mediates T cell trogocytosis to limit antitumor immunity is a research paper published in Journal of Clinical Investigation (2022). On theSindex it has a DataRank of 0. It has been cited 69 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIH Office of the Director
Grant: R01CA228181,R01CA222203,P50CA121973
NIH Office of the Director
Grant: NIH R01CA228181,R01CA222203,R01CA257265,P50CA257265
NIAID NIH HHS
Grant: U19 AI133524
NCI NIH HHS
Grant: R01 CA228181
NCI NIH HHS
Grant: P50 CA121973
NCI NIH HHS
Grant: R01 CA187975
NCI NIH HHS
Grant: R01 CA222203
NCI NIH HHS
Grant: P30 CA047904
NCI NIH HHS
Grant: R01 CA257265
National Institutes of Health
Grant: 5R01CA222203-03
Fecal Microbiota Transplant and PD-1 blockade in Melanoma
National Institutes of Health
Grant: 5R01CA187975-09
Regulation of stem-like CD8+ T cells and their role in immunotherapy
National Institutes of Health
Grant: 1R01CA257265-01
Neoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in Melanoma
National Institutes of Health
Grant: 3P30CA047904-07S1
CANCER CENTER SUPPORT GRANT
National Institutes of Health
Grant: 5R01CA228181-03
Targeting TIGIT and PD-1 in Melanoma
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals